Document series

Trial abstracts — page 5

700 structured trial abstracts. Each is one document in five parts: abstract, design and population, results, certainty assessment and citing documents.

Filter by text

Phase

Status

Showing 0 records on this page

Trial records

700 documents · page 5 of 30

Table 1. Trial records on this page. The table sorts on any column and filters on the controls above; both operate on the records shown on this page only.

Record	Compound	Phase	Status	Design	Randomised	Year	Certainty
KISS-IVF-TRIGGER	Kisspeptin-10	Phase 2	Reported	Single-arm open-label	60	2014	Low
LL37-PH1-2-VENOUSULCER	LL-37	Phase 1/2	Reported	Randomised, double-blind, placebo-controlled	34	2014	Low
DURATION-6	Exenatide	Phase 3	Reported	Randomised, open-label, active-controlled	911	2013	High
GETGOAL-DUO-1	Lixisenatide	Phase 3	Reported	Randomised, double-blind, placebo-controlled	446	2013	High
GETGOAL-L	Lixisenatide	Phase 3	Reported	Randomised, double-blind, placebo-controlled	495	2013	High
GETGOAL-M	Lixisenatide	Phase 3	Reported	Randomised, double-blind, placebo-controlled	680	2013	High
STEPS-2	Teduglutide	Phase 3	Reported	Single-arm open-label	88	2013	Moderate
TA1-SEPSIS-CN	Thymosin alpha-1	Phase 3	Reported	Randomised, double-blind, placebo-controlled	361	2013	Moderate
TB4-PH2-VENOUSULCER	Thymosin beta-4	Phase 2	Reported	Randomised, double-blind, placebo-controlled	72	2013	Low
STEPS	Teduglutide	Phase 3	Reported	Randomised, double-blind, placebo-controlled	86	2012	Moderate
TB4-PH1-CARDIAC	Thymosin beta-4	Phase 1	Reported	Phase 1 ascending dose	—	2012	Very low
IPA-PH2-POI	Ipamorelin	Phase 2	Terminated	Randomised, double-blind, placebo-controlled	—	2011	Not rated
KISS-DIAGNOSTIC	Kisspeptin-10	Phase 1	Reported	Diagnostic accuracy	—	2011	Low
TESA-PIVOTAL-1	Tesamorelin	Phase 3	Reported	Randomised, double-blind, placebo-controlled	412	2010	Moderate
TESA-PIVOTAL-2	Tesamorelin	Phase 3	Reported	Randomised, double-blind, placebo-controlled	404	2010	Moderate
LEAD-6	Liraglutide	Phase 3	Reported	Randomised, open-label, active-controlled	464	2009	High
DURATION-1	Exenatide	Phase 3	Reported	Randomised, open-label, active-controlled	295	2008	High
AOD-PH2B-OBESITY	AOD-9604	Phase 2b	Programme discontinued	Randomised, double-blind, placebo-controlled	536	2007	Not rated
GHKCU-TOPICAL-2	GHK-Cu	Phase 2	Reported	Randomised, double-blind, placebo-controlled	—	2007	Low
PRAM-OBESITY-PH2	Pramlintide	Phase 2	Reported	Randomised, double-blind, placebo-controlled	411	2007	Low
CJC-PH1-ASCENDING	CJC-1295	Phase 1	Reported	Phase 1 ascending dose	—	2006	Low
CJC-PH1-MULTIDOSE	CJC-1295	Phase 1	Reported	Phase 1 ascending dose	—	2006	Low
GHRP2-JP-DIAGNOSTIC	GHRP-2	Phase 3	Reported	Diagnostic accuracy	—	2006	Moderate
AMIGO-1	Exenatide	Phase 3	Reported	Randomised, double-blind, placebo-controlled	377	2005	High

page 5 of 30